If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.00    0.00 (0.00%)
Bid:
0.75
Ask:
1.25
Spread: 0.50 (66.667%)
Market Cap: £1.94m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Cultivated Meat Approved for Consumption in US

23 Jun 2023 11:30

RNS Number : 7591D
BSF Enterprise PLC
23 June 2023
 

23 June 2023

 

BSF Enterprise PLC

 

("BSF" or the "Company")

 

Cultivated Meat Approved for Consumption in US

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that cultivated meat has been approved for sale in the USA. As the US is one of the world's biggest consumers of meat, with approximately 40 billion kilograms consumed each year, this represents a significant step forward for the cultivated meat industry.

Two cultivated meat companies, UPSIDE Foods, Inc. ("UPSIDE Foods") and Eat JUST, have been granted regulatory approval from the joint USDA and FDA framework to sell their cultivated chicken products to US consumers. UPSIDE Foods plans to produce up to 22,000 kilograms of cultivated meat a year in the near-term with work having started on a larger operation with annual capacity of millions of pounds of cultivated meat products. Eat JUST intends to sell its products through a chain of restaurants through the US with the first to be opened shortly in Washington DC.

As one of the biggest markets in the world, with some of the most exacting standards for food safety, this development in the USA substantially validates cultivated meat as a viable and safe alternative to conventional meat. This paves the way for other countries to follow suit, other companies within the industry to receive approval, and ultimately full commercialisation of cultivated meat.

Che Connon, CEO of 3D Bio Tissues, said:

"This announcement marks a monumental milestone in the development of the Cultivated Meat industry. The US Government approval provides access to both UPSIDE Foods' and Eat Just's sustainable and ethical meat products in a country that is one of the world's biggest meat consumers. 

 "US regulations for food safety are some of the most stringent in the world. Today's approval will pave the way for the Government approval for other producers of cultivated meat in the US, including companies that 3D Bio Tissues is looking to partner with and provide our patented serum-free and animal-free cell booster City-MixTM to help scale up cultivated meat production.

"This decision has the potential to rapidly accelerate the development of the Cultivated Meat market in America and provides a clear framework for other countries to also follow." 

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Che Connon - CEO & Executive Director

Geoff Baker - Executive Director

 

 

Shard Capital (Broker)

Damon Heath

Isabella Pierre

0203 971 7000

 

 

SEC Newgate (Financial Communications)

Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. 

 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFFIRIIVFIV
Date   Source Headline
30th Jun 20267:00 amRNSInterim 2026 Results
26th Jun 20267:00 amRNSBSF Wins Cannes 2026 Awards for T-Rex Leather
16th Jun 20267:00 amRNSAuction Operational Update & Strategic Progress
12th Jun 20267:00 amRNSParis Auction Result
11th Jun 20267:00 amRNS£1 Million Convertible Loan Note
8th Jun 202611:59 amRNSShareholder meeting results
3rd Jun 20267:00 amRNSConditional Further Investment
2nd Jun 20268:50 amRNSTechnical White Paper on T-Rex Leather™
28th May 20267:00 amRNSAuction Update - May 2026
26th May 20267:00 amRNSStrategic Update May 2026
22nd May 20263:13 pmRNSPosting of Circular and Notice of General Meeting
5th May 20267:00 amRNST-Rex Leather™ handbag to be auctioned
17th Apr 202610:00 amRNSAdmission of Shares
13th Apr 20267:00 amRNSStrategic Shareholding Update
7th Apr 20267:00 amRNSWorld’s First T-Rex Leather Handbag Unveiled
2nd Apr 20267:00 amRNSWorld First T-Rex Leather™ Product
19th Mar 20267:00 amRNSSupply Agreement with SeaWith
17th Mar 20267:00 amRNSLGL Tanning Milestones
17th Mar 20267:00 amRNSLGL Tanning Milestones
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
13th Mar 20267:00 amRNSFurther Update on Fundraise & Reorganisation
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
10th Mar 202610:47 amRNSFirst Tannable A4-Sized Skin Achieved
3rd Mar 202611:00 amRNSResult of Annual General Meeting
27th Feb 20267:00 amRNSUpdate on Proposed Equity Fundraise
9th Feb 20267:00 amRNSNotice of 2026 AGM
3rd Feb 20265:14 pmRNSAnnual Financial Report - Correction
2nd Feb 20267:00 amRNSAnnual Financial Report
19th Jan 20267:00 amRNSKERATO LIMITED SIGNS WITH QUEBEC PSO GRANT
17th Dec 202511:08 amRNSResult of General Meeting
16th Dec 20257:00 amRNS3D Bio-Tissues Signs Supply Agreement with SeaWith
15th Dec 20257:00 amRNSChanges to timetable for proposed Equity Fundraise
5th Dec 20259:50 amRNS-RBSF Enterprise launches new Investor website
1st Dec 20257:02 amRNSProposed Equity Fundraise - Strategic Direction
1st Dec 20257:00 amRNSEquity Fundraise & Notice of General Meeting
29th Aug 202510:47 amRNSResignation of Chairman
10th Jul 20257:00 amRNSAgreement
25th Jun 20257:00 amRNSInterim 2025 Results
23rd May 20257:00 amRNS15p Warrants Amended
21st May 20257:00 amRNSLab-Grown Leather Ltd Progress
28th Apr 202510:01 amRNSStrategic Investment
25th Apr 20259:48 amRNSJoint Venture
13th Mar 20257:00 amRNS3DBT Lab Grown Leather Commercialization
6th Mar 20253:51 pmRNSPublication of a Prospectus
5th Mar 202512:10 pmRNSResult of Annual General Meeting
11th Feb 20258:21 amRNSExpected admission of shares - Replacement
11th Feb 20257:00 amRNSAIM Admission - Update
10th Feb 20257:00 amRNSAGM Statement
31st Jan 202512:41 pmRNSAnnual Financial Report
31st Jan 202512:31 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.